Brokerages predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce sales of $43.40 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $42.00 million and the highest estimate coming in at $44.70 million. Vanda Pharmaceuticals reported sales of $37.42 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16%. The company is expected to announce its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that Vanda Pharmaceuticals will report full-year sales of $192.20 million for the current fiscal year, with estimates ranging from $190.60 million to $193.80 million. For the next fiscal year, analysts anticipate that the business will report sales of $237.67 million per share, with estimates ranging from $223.00 million to $262.60 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.08. The firm had revenue of $44.28 million during the quarter, compared to analysts’ expectations of $44.00 million. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.94%. Vanda Pharmaceuticals’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.08 earnings per share.
VNDA has been the subject of a number of recent research reports. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Seaport Global Securities began coverage on shares of Vanda Pharmaceuticals in a report on Friday, January 19th. They issued a “buy” rating and a $20.00 price objective for the company. Oppenheimer set a $27.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, Jefferies Group restated a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.67.
In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 8,532 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $18.72, for a total transaction of $159,719.04. Following the completion of the sale, the chief financial officer now directly owns 208,066 shares in the company, valued at $3,894,995.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mihael Hristos Polymeropoulos sold 60,966 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $18.72, for a total transaction of $1,141,283.52. Following the completion of the sale, the insider now owns 1,243,838 shares of the company’s stock, valued at approximately $23,284,647.36. The disclosure for this sale can be found here. Insiders have sold 78,023 shares of company stock valued at $1,460,591 over the last 90 days. Corporate insiders own 7.60% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of Vanda Pharmaceuticals by 2.4% in the fourth quarter. BlackRock Inc. now owns 4,568,159 shares of the biopharmaceutical company’s stock valued at $69,436,000 after buying an additional 106,228 shares during the period. Spark Investment Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 8.2% in the fourth quarter. Spark Investment Management LLC now owns 383,400 shares of the biopharmaceutical company’s stock valued at $5,827,000 after buying an additional 29,000 shares during the period. Sei Investments Co. lifted its stake in shares of Vanda Pharmaceuticals by 3.5% in the fourth quarter. Sei Investments Co. now owns 277,088 shares of the biopharmaceutical company’s stock valued at $4,212,000 after buying an additional 9,417 shares during the period. Stonepine Capital Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 195.0% in the fourth quarter. Stonepine Capital Management LLC now owns 885,000 shares of the biopharmaceutical company’s stock valued at $13,452,000 after buying an additional 585,000 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Vanda Pharmaceuticals by 2.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 482,012 shares of the biopharmaceutical company’s stock valued at $7,327,000 after buying an additional 9,496 shares during the period. Institutional investors and hedge funds own 81.04% of the company’s stock.
NASDAQ:VNDA traded up $0.20 during trading hours on Tuesday, reaching $15.25. The company’s stock had a trading volume of 387,655 shares, compared to its average volume of 726,979. The stock has a market capitalization of $761.62, a PE ratio of -43.57 and a beta of 1.13. Vanda Pharmaceuticals has a one year low of $11.90 and a one year high of $20.40.
ILLEGAL ACTIVITY NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $43.40 Million” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/04/18/vanda-pharmaceuticals-inc-vnda-expected-to-announce-quarterly-sales-of-43-40-million.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.